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Summary of the scientific achievements 
Specific aim 1 
Endocannabinoids (eCBs) are retrograde lipid messengers regulating short- and long-term forms of synaptic 
plasticity throughout the nervous system (Chevaleyre et al., 2006). The substantial role of the eCB system in 
neuronal function is well supported by its involvement in various diseases of the CNS (Pacher et al., 2006). 
Several different mechanisms of eCB-dependent synaptic plasticity have been described in different layers of the 
neocortex, including stimulation-induced, pairing-induced, and spike-timing dependent depression (Birtoli and 
Ulrich, 2004; Nevian and Sakmann, 2006; Crozier et al., 2007). The exact molecular composition of synaptic 
eCB signaling is well described in some brain regions, e.g. the hippocampus, where activation of metabotropic 
glutamate receptors leads to the postsynaptic production of 2-arachidonoylglycerol (2-AG) by diacylglycerol 
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lipase (DGL)-α, and finally to the engagement of presynaptic type 1 cannabinoid receptors (CB1), inhibiting 
neurotransmitter release (Katona and Freund, 2008). Striking evidence has shown that enzymes and receptors of 
the delicate molecular machinery for eCB-mediated depression is required for the experience-dependent 
maturation of the developing somatosensory cortex (Hannan et al., 2001; Deshmukh et al., 2007; Wijetunge et 
al., 2008). However, in the neocortex, the molecular source of 2-AG release has not been assessed, and 
anatomical studies could not detect CB1 on glutamatergic axon terminals. Moreover, our knowledge was very 
limited on the molecular background of the massive laminar- and pathway-specific differences in the 
inducibililty of various forms of eCB-mediated depression. Thus, the aim of this project was to decipher the 
precise localization of the molecular source and target of eCB signaling, DGL-α and CB1, respectively, in 
various somatosensory cortical synapses. 
Objective 1 
To assess the cellular expression pattern of DGL-α, we carried out in situ hybridization (ISH) with digoxigenin- 
labeled riboprobes against a 1169 base long sequence of the DGL-α mRNA (Fig. 1). The staining revealed 
expression in cells throughout the forebrain, with moderate to high expression levels in the hippocampus, 
neocortex, thalamus, striatum and amygdala. In the somatosensory cortex, all pyramidal cell layers were labeled, 
with the highest intensity in layers II-III and V. These findings indicate that the vast number of principal cells 
express DGL-α in the somatosensory cortex, and overall in the forebrain. We also noted some sparsely located, 
weakly labeled cells in layer I of the neocortex, in which principal cells are absent indicating that DGL-α is also 




Figure 1. DGL-α mRNA is abundantly expressed 
throughout the forebrain and in the neocortex. (A), 
A low magnification micrograph of in situ 
hybridization against DGL-α mRNA reveals that 
principal cell layers show strong labeling in both 
the hippocampus and the neocortex. At higher 
magnification micrographs showing the primary 
somatosensory cortex (B), the pattern of DGL-α 
mRNA expression represents the laminar 
organization of the cortex, being the strongest in 
layers II-III and V. The lack of labeling in 
neighbouring sections hybridized with sense 
riboprobes suggests the specificity of the staining 












We have elucidated the subcellular localization of DGL-α in the somatosensory cortex using an antibody 
generated against an intracellular loop of this serine hydrolase (DGL-α INT, described by Katona et al., 2006). 
The staining resulted in a dense punctate pattern in the neuropil of all layers, strongest in layers I-IV, while cell 
bodies and dendritic segments of neurons remained immunonegative (Fig 2-3). Electron microscopic analysis of 
the stainings from 3 animals revealed that DGL-α is present postsynaptically in the majority (65.1±1.6%) of 
glutamatergic synapses, and, although at a substantially weaker level, in some (9.3±1.3%) GABAergic synapses 
as well (Fig 3). Using immunogold labeling, we have shown that the enzyme is precisely targeted to the plasma 
membrane of dendritic spines, at the close vicinity of synapses, but very rarely inside the postsynaptic density 
itself. Unfortunately, our collaborator (Prof. Andreas Zimmer) could not accomplish the generation of the 
proposed DGL-α knockout mice to date. However, we could obtain fixed brain samples of wild-type and DGL-α 
knockout animals (littermates) from Prof. Masanobu Kano, University of Tokyo. Immunostaining for DGL-α in 
these samples confirmed the specificity of the antibody we used in these studies (Figure 2). 
 
 
Figure 2. To confirm the specificity of our antibody and staining process, we performed DGL-α immunostaining on sections 
from wild-type (WT), and DGL-α knockout littermates (KO). The very low intensity of staining, and the lack of the 
characteristic punctate pattern in the KO sections indicates the specificity of the labeling. Scale bars: 100 μm for (A), 20 μm 
for (B). 
 
We attempted to reveal possible laminar- or pathway-specific variations in the molecular composition of the 
endocannabinoid system. First, we have utilized quantitative electron microscopic analysis of different 
neocortical layers to detect any difference in the presence of DGL-α at glutamatergic synapses. We have 
compared layers I, II-III and IV, all of which receive excitatory input from different sources, and express 
different forms of eCB-dependent plasticity. However, analysis of 300 spines of each layers (utilizing different 
antibody dilutions to avoid saturation of the sensitivity of the staining) detected no significant laminar 
differences in the ratio of immunoreactive synapses (p>0.4 with all dilutions, Kruskal-Wallis test, n=3 animals). 
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Figure 3. DGL-α is located postsynaptically at neocortical synapses. At the light microscopic level, DGL-α can be detected in 
all layers of the neocortex, with the highest intensities in layers I-IV, as revealed by peroxidase-based immunohistochemisty 
(A). At high-power micrographs of semithin sections (B), a punctate staining pattern can be observed in the neuropil, 
avoiding somata (asterisks) and dendritic shafts (arrowheads). At the electron microscopic level (C), DGL-α 
immunoreactivity could be observed in dendritic spines (sp), near asymmetric synapses (white arrowheads) raised by 
glutamatergic boutons (b). Immunogold labeling (D) revealed that the enzyme is confined to the postsynaptic plasma 
membrane, near the edge of the postsynaptic density. (E) While low levels of immunoreactivity (arrow) associated to 
symmetric synapses (double arrowheads) raised by GABAergic boutons can be detected in dendritic shafts (d), the striking 
accumulation of labeling in dendritic spines compared to shafts (F) indicates substantially higher enzyme levels at 
glutamatergic synapses. (G) Combined immunogold-immunoperoxidase stainings prove that DGL-α is present both at 
intracortical synapses (identified based on VGluT1 immunoreactivity), and at thalamocortical synapses (identified by either 
VGluT2 immunoreactivity, or the presence of anterograde tracer injected into the thalamus). Scale bars: 200 µm for (A), 20 
µm for (B), 200 nm for (C-F), 100 nm for (G). 
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Next, we studied the precise localization of the enzymes DGL-α and monoacylglycerol lipase (MGL) performing 
the synthesis and degradation, respectively, of the most abundant endocannabinoid, 2-AG in the human 
hippocampus (Ludányi et al., 2011). In the human hippocampus, immunoreactivity for DGL-α appeared to 
correspond with the distinct incoming glutamatergic pathways, and was particularly robust in the stratum 
radiatum (Figure 4). At high magnification, a dense granular pattern corresponding to DGL-α immunoreactivity 
was visible, which was located on the surface of immunonegative dendrites (Fig.4A). MGL immunoreacitivity 
proved to be very similar to that of DGL-α following the different layers of the human hippocampus. The pattern 
of immunostaining was also very similar at high magnification: the main immunonegative apical dendrites were 
covered with a dense punctate immunopositive signal (Fig. 4B). Further electron microscopic studies revealed 
that DGL-α-immunoreacitivity is present exclusively in the postsynaptic dendritic spine heads contacting 
asymmetric synapses (Fig. 4C). Conversely, MGL immunostaining was found presynaptically in the axon 
terminals of these excitatory synapses (Fig. 4D). Our anatomical findings show that the main enzymes 
responsible for 2-AG metabolism have the same subcellular localization in the mouse and human hippocampus 
suggesting an evolutionarily conserved role of 2-AG in retrograde signaling. As the components of the 
endocannabinoid system are potential molecular targets in numerous neurological diseases, their conserved 
localization may be of great importance in future drug discovery. 
 
Figure 4. Light- and electron microscopic distribution of enzymes responsible for 2-AG metabolism in the human 
hippocampus. DGL-α (A) and MGL (B) immunostaining appeared as a dense punctate pattern (arrowheads) in the radiatum 
layer of the human hippocampus, and highlighted the immunonegative apical dendrites of the pyramidal cells. At the electron 
microscopic level, DGL-α immunolabelling was only found in dendritic spines (s) receiving asymmetric synapses, but not in 
boutons (b) (C). Conversely, in the case of MGL-immunostaining, we found immunopositivity exclusively in the axon 
terminals (b), but not in the spines (s) (D). Scale, A-B, 20m, C-D, 500nm 
While ample evidence proves the role of CB1 on glutamate release and synaptic strength in the neocortex (e.g. 
Domenici et al., 2006), previous anatomical studies failed to detect CB1 on glutamatergic axon terminals of the 
primary somatosensory cortex (S1) (Bodor et al., 2005; Deshmukh et al., 2007). To assess the cellular and 
subcellular distribution of CB1 in principal neurons of the primary somatosensory cortex, we first performed ISH 
against CB1 mRNA. The stainings revealed the expression of the receptor in neocortical pyramidal cells, 
although at low levels compared to that of certain interneurons. The specificity of the staining has been verified 
using slices taken from CB1 knockout animals (produced by Prof. Andreas Zimmer, University of Bonn). Next, 
we carried out immunostainings with a highly sensitive antibody (Fukudome et al., 2004) to unequivocally 
confirm that CB1s are present on neocortical glutamatergic axon terminals (Fig. 5A-C). Double immunostaining 
against CB1 and DGL-α has revealed that these two key molecules of endocannabinoid signaling are indeed 
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targeted pre- and postsynaptically, respectively, to the same synapses (Fig. 5D). Finally, we have elucidated the 
synapse type-selective localization of CB1 utilizing double fluorescent immunostainings. While we could detect 
CB1 immunoreactivity on VGluT1-positive intracortical terminals, and on large GAD65-positive boutons of 
GABAergic interneurons, we haven’t found any sign of the presence of the receptor on VGluT2-positive 
thalamocortical terminals (Fig. 5E). 
 
Figure 5. Localization of CB1 receptor at neocortical synapses. (A) Immunofluorescence against CB1 receptor in the 
somatosensory cortex of wild-type (WT) and CB1 knockout (KO) littermates reveals specific labeling of fibers with large 
varicosities and small punctae, with a decreased density of the punctae in layer IV. (B) Electron micrographs of peroxide-
based staining indicate that the receptor is present in glutamatergic boutons (b), raising asymmetric synapses (white 
arrowheads) on dendritic spines (sp). (C) Immunogold labeling (arrows) reveals that CB1 is targeted to the plasma membrane 
of axon terminals, near synapses. (D) Double staining against CB1 (immunoperoxidase) and DGL-α (immunogold) shows 
that postsynaptic DGL-α and presynaptic CB1 are present in the same synapses. (E) Double immunofluorescent staining 
against CB1 and presynaptic markers of different pathways detected CB1 receptor on intracortical (VGluT1-positive), but not 
on thalamocortical (VGluT2-positive) glutamatergic axon terminals, and high levels of the receptor on a subset of 
GABAergic (GAD65-positive) boutons. Scale bars: 2 μm for (A) and (E), 200 nm for (B), and 100 nm for (C-D). 
As there is no evidence of CB1 receptors on thalamocortical axons or CB1 expression in the sensory thalamic 
nuclei, and none of the known plasticity mechanisms of thalamocortical synapses involve eCBs, it is very likely 
that these axon terminals are devoid of cannabinoid receptors. Interestingly, we could clearly demonstrate the 
presence of DGL-α postsynaptically to thalamocortical boutons, identified either based on VGluT2 
immunoreactivity or by anterograde tracer injections into the VPM (Figure 3G). Taken together, these results 
render the well-known homosynaptic modus operandi of eCB-mediated depression very unlikely at 
thalamocortical synapses, and raise the possibility of the presence of other, predominantly heterosynaptic eCB 
signaling mechanisms. 
Objective 3 
Although, unfortunately, we could not set up our own colony of DGL-α knockout mice, we have obtained brain 
samples from littermate wild type and DGL-α KO mice (described by Tanimura et al., 2010). To provide robust 
negative controls for our anatomical experiments, we carried out immunostainings, processing the WT and KO 
sections together throughout the procedure. Staining in the KO sections resulted in a very weak labeling of some 
sparsely scattered punctae (Fig. 3). According to our electron microscopical analysis, the majority of the residual 
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labeling in the KO was associated to dendritic mitochondria and microtubules, and to glial processes. In the wild 
type, 104 of 326 dendritic spines (~32%) contained the immunoreaction end product, while only 6 spines of 336 
(~2%) did in the knockout. Thus, we could unequivocally verify the results we have achieved using the “DGL-α 
INT” antibody. 
Objective 4 
Confirmation of the specificity of ISH and ICH experiments for DGL-α are discussed above in Objective 1 and 
3, respectively and demonstrated in Figure 1 and 2. 
Objective 5 
Input-dependent distribution of DGL-α was presented in Figure 3 and discussed under Objective 2.
Specific aim 2 
Objective 6 
We aimed to investigate the effect of mutations of DGL-α on the enzyme’s activity and localization in the 
excitatory synapses by the delivery of expression vector constructs into hippocampal primary neurons. 
First, we generated two vector constructs expressing DGL-α enzyme fused with green fluorescent protein (GFP). 
Using pAcGFP-C and pAcGFP-N expression vectors, we generated GFP-DGL-α N-terminally tagged (Fig. 6A) 
and DGL-α -GFP C-terminally tagged (Fig. 6C) fusion constructs, respectively. Following cloning, we selected 
the bacterial colonies carrying the appropriate construct by restriction enzyme digestion of the mini-prep DNA 
solution (Fig. 6B,D), and proved the lack of mutations by sequencing. 
 
Figure 6. Plasmid constructs expressing DGL-α tagged with green fluorescent protein. (A), Vector construct expressing GFP- 
DGL-α fusion-protein. Recognition sites for BshTI restriction enzyme are labelled. (B), Gel-electrophoretic analysis of 
restriction enzyme digestion of mini-preps showed that BshTI digestion resulted in the desired 6600bp and 1300bp long 
DNA products for example in the case of clone 1. (C), Vector construct expressing DGL-α-GFP fusion-protein. Recognition 
sites for NheI restriction enzyme are labelled. (D), Gelelectrophoretic analysis of restriction enzyme digestion of mini-preps 
showed that NheI digestion resulted in the desired 6000bp and 1800bp long DNA products for example in the case of clone 5. 
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Objective 7 
The DGL-α-GFP expression constructs were transfected into hippocampal primary neuronal cell culture using 
lipofectamine, and we examined whether the localization of the fluorescently labelled DGL-α is identical to the 
postsynaptic localization of native DGL-α. Light microscopic investigations revealed that the fluorescently 
labelled DGL-α is present in the dendrites of transfected hippocampal cells for both DGL-α-GFP and GFP-DGL-
α constructs (Fig.7A-B). To prove the correct postsynaptic localization of DGL-α-GFP fusion protein, we 
performed fluorescent immunostaining for the presynaptic marker Bassoon. GFP fluorescence and Bassoon 
immunostained puncta did not overlap at high magnification, however they were in close apposition with each 
other suggesting that DGL-α-GFP protein is localized in dendritic spineheads (Fig. 7B). In forthcoming electron 
microscopic experiments, we will prepare ultrathin sections of the transfected cells to further investigate the 
subcellular targeting of the fluorescently tagged DGL-α in our model system. 
 
 
Figure 7. Spine localization of GFP-tagged DGL-α in cultured hippocampal neurons. (A), GFP-DGL-α signal is enriched in 
the somatic plasma membrane and dendritic spines of a DIV21 neuron. (B) In distal dendrites, DGL-α is concentrated into 
punctae contacting the presynaptic active zone marker Bassoon, indicating postsynaptic targeting of the construct. Scale bars: 
10 µm for (A), 5 µm for (B). 
Objective 8 
In the proposed project plan, we aimed to investigate the role of DGL-α and DGL-β enzymes in mGluR-
mediated synaptic plasticity using silencing RNAi constructs. We did not pursue this research direction further, 
because Tanimura and colleagues published a paper in Neuron in 2010 investigating the same question. They 
have generated DGL-α and DGL-β knockout mice to study the contribution of these enzymes to retrograde 
signaling. They have shown that the suppression of endocannabinoid-mediated retrograde signaling is impaired 
in the DGL-α knock-out mice, but is intact in DGL-β knock-out animals, so 2-AG synthesised by DGL-α is 
responsible for mediating the suppression of synaptic retrograde signaling. 
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Objective 9 
Using an in silico search, we have identified serine residues of the C-terminal tail of DGL-α that are potentially 
available for phosphorylation, and thus might regulate the activity and localization of the DGL-α enzyme. These 
serine residues (S723, S730, S733, S804, S808) are evolutionarily conserved (Fig. 8, top), and are indeed 
phosphorylated according to proteomic analysis of synaptic preparations. To investigate the role of activity-
dependent phosphorylation of DGL-α at these serine residues, we generated loss-of-function mutations of these 
selected serines to alanine. We used a site-directed mutagenesis technique to generate these constructs from 
fluorescently labelled DGL-α expression vectors. We optimized the method to achieve ~95% success rate for 
mutagenesis based on colour-dependent selection of transformed bacterial colonies, which was further verified 
by sequencing. Using the correct primers (Fig. 8, bottom), this rapid and reliable technique allows the 
preparation of loss-of-function mutants in the DGL-α-GFP fusion protein expressing vectors to investigate the 
effect of these mutations on the anatomical localization and physiological function of DGL-α in the subsequent 
experiments. 
 
                723   730  733             804   808 
Human           SSVRSKSQSEMSLEGFSE  DSRRSSGFRSIRGSPSL 
Chimpanzee      SSVRSKSQSEMSLEGFSE  DSRRSSGFRSIRGSPSL 
Rhesus          EPVGSKSQSEMSLEGFSE  DSRRSSGFRSIRGSPSL 
Rat             SSVRSKSQSEMSLEGFSE  DSRRSSGFRSIRGSPSL 
Mouse           SSVRSKSQSEMSLEGFSE  DSRRSSGFRSIRGSPSL 
Chicken         SSTKSKSHSEISLEGFYE  DSRRSSGFRSIRGSPSL 
Danio           SSVRSCARSEISLDGFSE  DSRRSSA—-ALRGSPCL 
Pufferfish      SSVRSCAQSEISLDGFSE  DSRRSSA—-ALRGSPML 
 
S723A: AGT  GCT 
forw S723A: AGAGCATCGCAACAGCGCTGTCAGGAGCAAGTC 
rev S723A: GACTTGCTCCTGACAGCGCTGTTGCGATGCTCT 
 
S730A: TCT  GCT 
forw S730A: CAGGAGCAAGTCTCAGGCTGAGATGAGTCTGG 
rev S730A: CCAGACTCATCTCAGCCTGAGACTTGCTCCTG 
 
S733A: AGT  GCT 
forw S733A: GTCTGAGATGGCTCTGGAGGGCTTCTCT 
rev S733A: AGAGAAGCCCTCCAGAGCCATCTCAGAC 
 
S804A: AGC  GCC 
forw S804A: CTCCTCAGGCTTCCGAGCCATCAGAGGCTCGCCCAG 
rev S804A: CTGGGCGAGCCTCTGATGGCTCGGAAGCCTGAGGAG 
 
S808A: TCG  GCG 
forw S808A: CCGAAGCATCAGAGGCGCGCCCAGCCTCCATGC 
rev S808A: GCATGGAGGCTGGGCGCGCCTCTGATGCTTCGG 
 
Figure 8. Top: Candidate phosphorylated serine (S) residues of DGL-α indentified by in silico analysis of proteomic studies 
using synaptic preparations. Note that the serine residues that might be target for activity-dependent phosphorylation 
(highlighted in black) are evolutionarily conserved in phylogenetically distant species. Bottom: Primer sequences used for 
loss-of-function mutation of serine residues, mutated nucleotides are in red. 
We also planned to address the role of a conserved Homer binding motif in DGL-α and the long isoforms of 
Homer in coupling DGL-α and mGluR in the perisynaptic signaling machinery. However, we finally did not 
perform these experiments, because the role of Homer in the regulation of DGL-α activity has been revealed by 
the group of Stephan Ikeda (Won et al, 2009). They have prepared a model system in isolated rat sympathetic 
neurons by sequential addition of molecular components to investigate the minimal molecular requirement for a 
functional endocannabinoid system. They identified mGluR5a, Homer 2b, DGL-α and CB1 receptors as critical 
elements required to recapitulate retrograde endocannabinoid production and detection, thus confirming our 
original hypothesis. 
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Therefore we chose an alternative approach to study the regulation of DGL-α. We examined the role of DGL-
αand mGlu5 coupling in Fragile X syndrome (FXS). Fragile X syndrome is the most common form of inherited 
mental retardation and is caused by genetic silencing of the fmr1 gene, resulting in loss of the fragile X mental 
retardation protein (FMRP). The “mGlu-Theory” of FXS states that enhanced group I metabotropic glutamate 
receptor (mGlu) activity may explain the phenotypic manifestation of FXS (Bear et al., 2004). Glutamatergic 
synapses in the nucleus accumbens express a form of long term depression (LTD) requiring endocannabinoid 
(eCB) production via activation of postsynaptic mGlu5 receptors and their coupling to DGL-α (Robbe et al., 
2003). Based on the “mGlu-theory”, we expected an enhancement of this form of synaptic plasticity at these 
synapses, however to our surprise; mGlu5-induced-LTD was completely absent in FMR1-/- mice (Figure 9A). 
Other synaptic properties were normal in both groups, basal eCB levels and CB1 receptor function was unaltered 
(data not shown), however a significant decrease in mGlu5-induced DGL-α activity was observed in 
synaptoneurosomes prepared from FMR1-/- mice (Figure 9B), suggesting that FMRP loss resulted in a specific 
functional uncoupling of mGlu5 from DGL-α. To test this hypothesis, we performed a detailed electron 
microscopy study, which revealed that DGL-α distribution was concentrated perisynaptically at glutamatergic 
synapses in wild type, but not in FMR1-/- mice (Figure 9C). Instead, DGL-α was distributed sporadically along 
the spine head membrane and often within the spine head cytoplasm in FMR1-/- animals. Interestingly, a similar 
biased perisynaptic distribution of mGlu5 was found in both groups (Figure 9D), suggesting that DGL-α is 
specifically mis-targeted following FMRP knockout. Thus, we conclude that absence of FMRP results in loss of 
eCB-LTD in the nucleus accumbens, which may be explained by functional uncoupling of mGlu5 and DGL-α at 
glutamatergic synapses. 
 
Figure 9. Fragmentation of the eCB system following 
FMRP knockout 
(A) Activation of mGluR5 with 50 µM (S)-DHPG 
induces long term depression in wild type littermates 
(open circles) but not FMR1-/- mice (filled circles). 
Summary graph showing excitatory post synaptic 
field potentials (fEPSP) amplitudes. Values are 
normalized to baseline before the induction of LTD 
and averaged per minute. 
(B) Synaptoneurosomes were prepared from whole 
brain of wild-type or FMR1-/- mice. The fractions (1 
mg/ml) were incubated at 37 °C for the indicated 
time in the presence or absence of 100 μM DHPG 
and DGL activity was measured (n=3). 
(C) (i, ii) Light micrographs of DGL-α 
immunoperoxidase labeling in WT (i) and FMR1-/- 
mice (ii). The granular staining of DGL-α-
immunoreactivity in the neuropil of the nucleus 
accumbens suggests a compartmentalized 
localization of the enzyme in WT and FMR1-/- mice. 
Medium spiny neuron somata are largely devoid of 
labeling (asterisks). aco – anterior commissure, s – 
spine head, b - bouton. (iii, iv) Electron micrographs 
of asymmetric synapses displaying DGL-α-
immunogold labeling, in WT (iii) and FMR1-/- mice 
(iv). Gold particles representing the precise 
localization of DGL-α (arrowheads) are 
predominantly found in the perisynaptic domain 
close to the PSD (small arrows) in WT animals, 
whereas in synapses from FMR1-/- animals, gold 
particles are usually found in more distal locations 
from the PSD. (v) Histogram summarizing the 
skewed perisynaptic distribution of normalized 
DGL-α-immunogold particles on the plasma membrane of dendritic spine heads in WT mice (black bars, n = 259), and the 
lack of biased distribution in FMR1-/- mice (grey bars, n = 185). Large arrowhead represents the edge of the PSD. 
(D) (i, ii) Light micrographs of mGlu5 immunoperoxidase labeling in WT (i) and FMR1-/- animals (ii). mGlu5-
immunoreactivity displays a similar granular pattern of labeling as DGL-α, with medium spiny neuron somata largely devoid 
of labeling (asterisks). aco – anterior commissure, s – spine head, b - bouton.  (iii, iv) Electron micrographs of asymmetric 
synapses displaying mGlu5-immunogold labeling (arrowhead), in WT (iii) and FMR1-/- animals (iv). In contrast to DGL-α 
localization, mGlu5 was predominantly found in the perisynaptic domain adjacent to the PSD (red arrows) in both WT and 
FMR1-/- mice. (v) Histogram representing the similar normalized distribution of mGlu5-immunogold particles on dendritic 
spine heads in WT (black bars, n = 294) and FMR1-/- animals (grey bars, n = 285). Large arrowhead points to the edge of the 
PSD. Scale bars: 15 μm in Ci, Cii, Di, Dii and 100 nm in Ciii, Civ, Diii, Div. 
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Specific aim 3 
Diacylglycerol lipases generate monoacylglycerols by the cleavage of diacylglycerols. Two isoforms of this 
enzyme have been cloned (Bisogno et al., 2003), of wich the α isoform has been identified as the synthetic 
enzyme of synaptic endocannabinoids (Katona et al., 2006; Tanimura et al., 2010). However, knockout of the 
second isoform, DGL-β, did not alter neither endocannabinoid-mediated synaptic plasticity, nor brain 2-AG 
levels (Tanimura et al., 2010). Thus, the function of this enzyme in the adult brain has remained elusive to date. 
To aid generation of hypotheses for the role of DGL-β, in our third specific aim, we have attempted to assess the 
expression pattern and subcellular localization of the enzyme. Our preliminary in situ hybridization and 
immunostaining results suggested that DGL-β is abundantly expressed by adult mouse hippocampus and cortex, 
and, at the protein level, the enzyme is targeted to the postsynaptic plasma membrane, near symmetric, 
putatively GABAergic synapses. While similar staining patterns with multiple antibodies raised against 
independent epitopes suggested the specificity of stainings, lack of access to DGL-β knockout animals prevented 
the rigorous verification of the results.  
Objectives 1,2,3,4,5 and  8 (corresponding to DGL-β experiments) 
To overcome the limitations of using antibodies, we have first generated EGFP-tagged DGL-β constructs to 
study the localization of the enzyme in cultured primary hippocampal neurons. We have successfully cloned the 
coding sequence of the DGL-β gene from cDNA reverse transcribed from total adult mouse hippocampal RNA, 
thus, in spite of the lack of knockout control for our ISH results, we could unequivocally prove DGL-β 
expression in the adult brain at the mRNA level. Transfection of cultured neurons with DGL-β tagged either on 
the N- or on the C-terminal revealed the somatodendritic targeting of the enzyme (Fig. 10). The signal was 
accumulated in discrete punctae in dendrites, both in shafts and spines. Our preliminary electron microscopic 
results of anti-EGFP immunogold stainings of cultured neurons suggest that surprisingly, unlike DGL-α, the β 
isoform is not targeted to the plasma membrane, but localized on intracellular membrane compartments. Using 
the constructs, we could directly test the sensitivity of our different antibodies on transfected neurons (Fig. 11). 
All of our antibodies detected overexpressed DGL-β, however, certain antibodies also stained somata of 
untransfected cells, questioning their specificity. 
Figure 10. Generation of tagged DGL-β constructs 
(A) Maps of constructs of DGL-β tagged on the C- 
and N-terminal. (B) Confocal micrographs of DIV21 
primary hippocampal neurons expressing either 
construct reveal somatodendritic localization of 
tagged DGL-β. (C) The tagged enzyme has 
accumulated in punctae inside dendritic shafts and 












Figure 11. Schematic representation of DGL-β depicting the location of epitopes used to generate antibodies. The lipase3 
motif, and the region targeted in the knockout by Kano et al. are also marked. We have verified the sensitivity of the 
antibodies utilizing cultured primary hippocampal neurons overexpressing DGL-β. Note the cytoplasmic immunoreactivity of 
untransfected cells using the C- and N-terminal antibodies. Scale bar: 10 μm. 
We have set up a collaboration with Prof. Andreas Zimmer to gain access to DGL-β knockout mice for the 
essential negative control experiments. Unfortunately, Prof. Zimmer could not accomplish the generation of the 
mice to date. However, while we could not set up our own breeding colony, we have received fixed brains of 
littermate wild type (WT) and DGL-β knockout (KO) mice from Prof. Masanobu Kano (described by Tanimura 
et al., 2010). Immunostainings resulted in the same intensity and pattern in WT and KO samples (Fig. 12), 
indicating very strong aspecific binding of all of our antibodies, rendering them useless for 
immunohistochemical applications.  
Taken together, while, due to technical limitations, we could not accomplish our objectives as planned, using 
alternative methods, we could confirm the expression of DGL-β in the adult rodent hippocampus, and the 
somatodendritic localization of the enzyme in cultured hippocampal neurons. We are working on the generation 




Figure 12. Immunostainings with antibodies raised against 3 independent epitopes has resulted in similar staining patterns in 
the hippocampus of wild-type (WT) and DGL-β knockout (KO) animals. Scale bars: 100 μm/20 μm. 
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